المنتجات

PORTEC 3 Possible benefit with combined CT RT in high risk

Jun 15 2017 Combined chemotherapy and radiotherapy showed a trend toward improved FFS vs radiotherapy alone in patients with high risk endometrial cancer

Adjuvant treatment for high risk endometrial cancer European

04 09 2017 Upfront pathology review in the randomised PORTEC 3 trial for high risk endometrial cancer 29th European Congress of Pathology PORTEC 3 international collaborators Stephanie de Boer Department of Radiation Oncology Leiden University Medical Center the Netherlands PORTEC 3

No OS Benefit With Chemoradiotherapy in High Risk Endometrial

Feb 23 2018 Adjuvant chemotherapy given during and after radiotherapy did not improve 5 year overall survival for patients with high risk endometrial cancer in the phase III PORTEC 3 trial

Toxicity and quality of life after adjuvant chemoradiotherapy versus

Lancet Oncol 2016 Aug 17 8 1114 1126 doi 10 1016 S1470 2045 16 30120 6 Epub 2016 Jul 7 Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high risk endometrial cancer PORTEC 3 an open label multicentre randomised phase 3 trial de Boer SM 1 Powell

Final results of the international randomized PORTEC 3 trial of

5502 Background Women with high risk endometrial cancer HREC are at increased risk of distant metastasis and endometrial cancer related death The randomized PORTEC 3 intergroup trial was initiated to investigate the benefit of adjuvant chemotherapy during and after radiotherapy CTRT versus pelvic